Dr. David Healy is a world-renowned psychiatrist, psychopharmacologist, neuropsycopharmacologist, scientist, and author. He undertook his doctoral research on the serotonin system on which antidepressants work, while qualifying in psychiatry. He moved to Cambridge University for higher training in psychiatry and to engage in post-doctoral research.
He has since been a Professor of Psychiatry in Cardiff University and Bangor University, working clinically in Britain’s National Health Service for 30 years before recently being appointed as a Professor of Psychiatry in the Department of Family Medicine at McMaster University in Canada. He is licensed to practice medicine in the U.K., Ireland, and Canada.
His clinical work has involved the full gamut of clinical activities, from inpatient care to outpatient and community care, covering all mental health conditions, including organic, psychotic, drug dependence, and personality-based conditions in all ages, from centenarians to adolescents. His main areas of research include the contribution of psychotropic drugs to suicide, for which he was one of the first researchers to make this link; adverse effects of drugs; conflict of interest between pharmaceutical companies and academic medicine; and the history of pharmacology. His combined clinical and pharmacology background led to his role as Secretary of the British Association for Psychopharmacology in the early 1990s and consultancies with most pharmaceutical companies, including AstraZeneca, Boots Pharmaceuticals, Eli Lilly, Janssen Pharmaceuticals, Lundbeck Organon, Pharmacia-Upjohn, Rhone-Poulenc Rorer, Pfizer, and SmithKline Beecham. Further, Dr. Healy has conducted clinical trials, given lectures, and chaired symposia for these companies, and knows how industry works better than the CMOs or those they have consulted in coming to their view.
DR. DAVID HEALY ON OUR “KNOW RISKS” PODCAST